October 25, 2026 Leave a comment

Plasmid DNA in a Fatal Heart Tumor:

Why the Residual-DNA Question Can No Longer Be Waved Away

· @Thomas Lee Abshier, ND

Where I stand

I stand with those who believe residual plasmid DNA in mRNA COVID-19 vaccines is a real, unresolved safety question, and that a new case report from the McCullough Foundation makes it more urgent to answer. The report describes vaccine-sequence DNA fragments recovered from a fatal heart tumor in a previously healthy 35-year-old man.

One case cannot prove that the vaccine caused his cancer. What it does is raise a specific, testable question: did synthetic DNA delivered by the vaccine end up inside a malignant tumor, and if so, did it play any part? That question deserves an independent answer, not a dismissal.

Below I set out the case, the areas of genuine uncertainty, and the reasons the concern remains plausible.

The case

The report is titled “Fatal Cardiac Intimal Sarcoma in a 35-Year-Old Male Following COVID-19 mRNA Vaccination: Plasmid DNA Fragments Encoding the S-Protein Detected in Tumor Tissue.” Nicolas Hulscher, MPH, of the McCullough Foundation, announced its findings on September 9, 2026. As of this writing, I have not been able to locate the full paper in an indexed medical journal, so the details below are as the authors have described them.

  • The patient. A 35-year-old man with no personal or family history of cancer and no identified hereditary predisposition.
  • Vaccination. Pfizer-BioNTech (BNT162b2) on April 10 and May 4, 2021.
  • Diagnosis. 170 days after the first dose, doctors found a tumor filling the left atrium of his heart, with multiple metastases already in the brain.
  • Pathology. Surgeons removed a 9.0 × 7.0 × 5.3 cm mass. It was a high-grade cardiac intimal sarcoma, with the MDM2 and KDR amplification typical of that cancer. PET/CT found no other primary tumor.
  • Course. Despite open-heart surgery, chemotherapy, radiation, gamma knife treatment, and four brain operations, new metastases kept appearing. He died 675 days after diagnosis, after bleeding into a brainstem tumor.
  • Growth rate. One brain metastasis grew from about 4 mm to 35 mm in 94 days, a volume doubling time of roughly 10 days.
  • The molecular finding. PCR on archived tumor tissue detected three separate codon-optimized vaccine spike-gene fragments and the plasmid origin-of-replication sequence. The SV40 enhancer was not detected. A separate analysis found no intact spike protein and no SARS-CoV-2 nucleocapsid protein in the tissue.

Cardiac intimal sarcoma is genuinely rare. Primary heart tumors turn up in roughly 0.001–0.03% of autopsies, about a quarter of them are malignant, and intimal sarcoma is one of the less common types. Case series describe it as aggressive, with survival commonly measured in months to a year or two.

What the finding does and does not yet show

The central fact, if it holds up, is that vaccine-derived DNA reached the tumor. That is worth knowing. These are the areas of uncertainty that stand between that fact and a conclusion about cause.

Presence is not cause. Vaccine lipid nanoparticles travel through the bloodstream, and tumors are richly supplied with blood. Finding vaccine DNA in a tumor tells us the DNA got there. It does not tell us whether the DNA started the cancer, sped it up, or simply arrived as a passenger. The report does not show that the fragments integrated into the tumor’s genome, which a direct causal mechanism would most likely require.

Controls decide the meaning. The essential comparisons are not described in the public announcement: the same patient’s normal tissue, tumors from vaccinated people who did not have unusually aggressive cancers, and tumors from unvaccinated people run through the same assay. Vaccine plasmid sequences are also common in laboratories, and archived tissue is vulnerable to contamination. Without these controls, a positive PCR result is suggestive, not conclusive.

The clock is ambiguous. A 9 × 7 × 5.3 cm mass contains about 100 billion cells, roughly 37 doublings from a single cell. At the 10-day doubling time measured in the brain metastasis, that is roughly a year of growth, longer than the 170 days since the first dose. Early tumor growth is often faster than later growth, so this does not rule out onset after vaccination. It does mean the timing alone cannot tell us whether the tumor began before or after the first shot, which is exactly what the authors’ own model (acceleration of a hidden, pre-existing clone) allows.

The tumor has a known driver. MDM2 amplification is the characteristic molecular event in intimal sarcoma and is found in cases with no vaccine exposure. Its presence here fits the cancer’s normal biology and does not, by itself, point to an outside cause.

A single case is a signal, not a rate. Case reports are how many real drug harms were first noticed. They are also how many false alarms began. Only systematic study can tell which this is.

Why the concern remains plausible

The uncertainties above are real, but they do not make the concern go away. Several independent lines keep it alive.

Residual DNA is admitted, not imagined. These vaccines’ mRNA is transcribed from a DNA plasmid template. Manufacturers digest the plasmid afterward, and the European Medicines Agency acknowledges that small amounts of plasmid DNA fragments remain in the finished product. The debate is not over whether it is there, but over how much, in what form, and with what effect.

The amount is disputed. Regulators cite a ceiling of 10 nanograms of residual DNA per dose, and the FDA, EMA, and Germany’s Paul-Ehrlich-Institut report that released lots comply. Independent groups using different methods have reported higher levels. In August 2026, Kevin McKernan, David Speicher, and Jessica Rose argued in Oncotarget that a major 2025 study found no excess DNA because its methods systematically undercounted it, and that correcting for fragmentation pushes one of its own measurements past the 10 ng limit. Manufacturers counter that the independent methods overcount by mistaking RNA for DNA. No independent, agreed method has settled that disagreement.

The delivery vehicle is new. Residual-DNA limits grew out of decades of experience with conventional biologics, where stray DNA floats free in the product. In mRNA vaccines, fragments can be packaged in lipid nanoparticles built specifically to carry nucleic acids into cells. Critics argue that a limit set for loose DNA does not address DNA delivered into cells. The FDA says its review considered the whole product, including the nanoparticles, but has not published a study designed around that specific question.

Population data raise a flag. A 2025 South Korean cohort study of about 3 million matched people in Biomarker Research reported associations between COVID-19 vaccination and higher one-year risk of six cancers, including thyroid, gastric, colorectal, lung, and breast. Critics have pointed to design problems, including different start dates for the vaccinated and unvaccinated groups and a focus on cancers that are routinely screened. The study shows association, not cause. It is still a reason to look harder, not to stop looking.

The intuition is not foolish. Injecting synthetic, codon-optimized genetic material packaged to enter cells, into billions of people, on an accelerated timeline, is a departure from anything medicine had done before. A patient’s sense that this deserves extra caution is a reasonable instinct, not superstition.

The incentives cut one way. The COVID-19 vaccines earned their makers tens of billions of dollars. Under the PREP Act, manufacturers are shielded from most liability for injuries. Safety data for lot release come largely from the manufacturers themselves. None of this proves wrongdoing. It does mean that the parties best placed to investigate this question have the least reason to want an unfavorable answer, which is precisely why independent investigation matters.

What should happen now

The right response to a single striking case is neither to bury it nor to treat it as settled. It is to test it. Specifically:

  1. Publish the full report with its methods and controls. Include primer sequences, contamination controls, and results from the patient’s normal tissue so other laboratories can verify the work.
  2. Replicate it independently. A laboratory with no stake in the outcome should test the same archived tissue, blinded to what it is.
  3. Test tumors systematically. Cancer registries and tumor banks can compare vaccine-sequence DNA in tumors from vaccinated and unvaccinated patients, and look for integration into the tumor genome rather than mere presence.
  4. Settle the measurement dispute. Regulators, manufacturers, and independent critics should agree on a validated method to measure residual DNA in finished vials and apply it to retained lots.
  5. Address the nanoparticle question directly. Whether the 10 ng limit is adequate for DNA packaged in lipid nanoparticles should be studied and answered in public, not assumed.
  6. Tell patients what is known and unknown. Informed consent for mRNA products should state that residual DNA fragments are present and that their long-term effects are still being studied.

For patients

If you received an mRNA vaccine, this case is not a reason for panic. Cardiac intimal sarcoma remains extremely rare, and nothing yet shows that vaccinated people as a group face it at a higher rate.

It is worth paying attention to. Unexplained shortness of breath, fainting, new palpitations, persistent chest symptoms, or new neurological symptoms deserve prompt evaluation, whatever their cause. Tell your physician your vaccination history so it becomes part of the record, and ask that they report any suspected injury to VAERS. You and your physician make decisions about future vaccination with the full picture, including what is still unknown.

References

Leave a Reply

Your email address will not be published. Required fields are marked *